MOSER TOBIAS
Universitätsklinik für Neurologie
Publikationen
32 Publikationen
2023
Beiträge in Fachzeitschriften
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Seiberl, M; Feige, J; Hilpold, P; Hitzl, W; Machegger, L; Buchmann, A; Khalil, M; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Int J Mol Sci. 2023; 24(4):
Originalarbeiten (Zeitschrift)
2022
Beiträge in Fachzeitschriften
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery.
Feige, J; Berek, K; Seiberl, M; Hilpold, P; Hitzl, W; Di Pauli, F; Hegen, H; Deisenhammer, F; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Neurol Int. 2022; 14(4): 943-951.
Originalarbeiten (Zeitschrift)
The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation
Harrer, C; Otto, F; Radlberger, RF; Moser, T; Pilz, G; Wipfler, P; Harrer, A
CELLS-BASEL. 2022; 11(17): 2649
Übersichtsarbeiten
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.
Moser, T; OSullivan, C; Otto, F; Hitzl, W; Pilz, G; Schwenker, K; Mrazek, C; Haschke-Becher, E; Trinka, E; Wipfler, P; Harrer, A;
Ther Adv Neurol Disord. 2022; 15: 17562864221092092
Originalarbeiten (Zeitschrift)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser, T; Otto, F; OSullivan, C; Hitzl, W; Pilz, G; Harrer, A; Trinka, E; Wipfler, P;
Mult Scler Relat Disord. 2022; 59: 103560
Originalarbeiten (Zeitschrift)
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
Moser, T; Ziemssen, T; Sellner, J;
Wien Med Wochenschr. 2022; 172(15-16):365-372
Originalarbeiten (Zeitschrift)
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
O Sullivan, C; Zach, F; Moser, T; Pilz, G; Harrer, A; Trinka, E; Enzinger, C; Pfaff, JAR; Wipfler, P;
J Neurol. 2022; 269(2):616-618
Letter
The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.
Wiesinger, AM; Bigger, B; Giugliani, R; Scarpa, M; Moser, T; Lampe, C; Kampmann, C; Lagler, FB;
FRONT PHARMACOL. 2022; 13: 863667
Übersichtsarbeiten
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications
Moser, T; Otto, F; Pilz, G; Wipfler, P
EUR J NEUROL. 2022; 29: 395-395.
Abstracts (Zeitschrift)
2021
Beiträge in Fachzeitschriften
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis.
Moser, T; Hoepner, L; Schwenker, K; Seiberl, M; Feige, J; Akgün, K; Haschke-Becher, E; Ziemssen, T; Sellner, J;
Cells. 2021; 10(11):
Originalarbeiten (Zeitschrift)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Originalarbeiten (Zeitschrift)
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; OSullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P;
Front Immunol. 2021; 12:718895
Originalarbeiten (Zeitschrift)
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Radlberger, RF; Sakic, I; Moser, T; Pilz, G; Harrer, A; Wipfler, P;
Mult Scler Relat Disord. 2021; 48:102727
Originalarbeiten (Zeitschrift)
Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
Seifert-Held, T; Eberhard, K; Lechner, C; Macher, S; Hegen, H; Moser, T; Jacob, GB; Puttinger, G; Topakian, R; Guger, M; Kacar, E; Zoche, L; De Simoni, D; Seiser, A; Oberndorfer, S; Baumgartner, C; Struhal, W; Zimprich, F; Sellner, J; Deisenhammer, F; Enzinger, C; Reindl, M; Rauschka, H; Berger, T; Höftberger, R;
Front Immunol. 2021; 12: 641106
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Extensive Long-term Immune Cell Profiling Reveals Further Targets of Oral Cladribine in MS
Moser, T; Ziemssen, T; Sellner, J
NEUROLOGY. 2021; 96(15):
Abstracts (Zeitschrift)
2020
Beiträge in Fachzeitschriften
Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats.
Feige, J; Moser, T; Bieler, L; Schwenker, K; Hauer, L; Sellner, J;
Nutrients. 2020; 12(3):
Übersichtsarbeiten
Clinical Challenges in a 49-Year-Old Patient with Severe Tick-Borne Myeloradiculitis Despite Complete Active Vaccination.
Feige, J; Moser, T; Hauer, L; Pikija, S; Sellner, J;
VACCINES-BASEL. 2020; 8(1):
Fallberichte
The role of TH17 cells in multiple sclerosis: Therapeutic implications.
Moser, T; Akgün, K; Proschmann, U; Sellner, J; Ziemssen, T;
Autoimmun Rev. 2020; 19(10):102647
Übersichtsarbeiten
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
Moser, T; Schwenker, K; Seiberl, M; Feige, J; Akgün, K; Haschke-Becher, E; Ziemssen, T; Sellner, J;
Ann Clin Transl Neurol. 2020; 7(11):2199-2212
Originalarbeiten (Zeitschrift)
Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype.
Otto, F; Moser, T; Feige, J; Seiberl, M; Bieler, L; Sellner, J;
Mult Scler Relat Disord. 2020; 42: 102108
Fallberichte
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.
Radlberger, RF; Moser, T; Schwenker, K; Harrer, A; Wipfler, P;
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.. 2020; -ÖGN 2020 – 17. Jahrestagung der österreichischen Gesellschaft für Neurologie, Salzburg, 20.-21. September, 2020
; 20.-21.09.2020; SALZBURG.
Abstracts (Zeitschrift)
2019
Beiträge in Fachzeitschriften
Cerebral Vasculitis in Crohns Disease: Always a Complication of Inflammatory Bowel Disease or Tumor Necrosis Factor-Alpha Inhibition?
Moser, T; Bubel, NE; Machegger, L; Pikija, S; Sellner, J;
Inflamm Bowel Dis. 2019; 25(12):e160-e161
Letter
Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety.
Moser, T; Harutyunyan, G; Karamyan, A; Otto, F; Bacher, C; Chroust, V; Leitinger, M; Novak, HF; Trinka, E; Sellner, J;
Brain Sci. 2019; 9(10):
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Initial real-life experience with ocrelizumab in patients with relapsing-remitting and primary progressive multiple sclerosis in Salzburg, Austria
Feige, J; Moser, T; Nagy, Z; Otto, F; Wipfler, P; Trinka, E; Sellner, J;
EUR J NEUROL. 2019; 26: 489-489.
Abstracts (Zeitschrift)
Coexpression analysis of alpha-4 and beta-1 reveals VLA4-related subset heterogeneity and the VLA4(hi) phenotype associated with JCV seropositivity
Harrer, A; Frommrich, M; Moser, T; Federspieler, A; Wipfler, P; Afazel, S; Kraus, J; Haschke-Becher, E; Sellner, J
MULT SCLER J. 2019; 25: 447-447.
Abstracts (Zeitschrift)
Neuroborreliosis with cranial polyradiculitis and progressive brain stem infarction in a Crohnxxxs disease patient with anti-tumor necrosis factor-alpha therapy
Moser, T; Bubel, N; Pikija, S; Machegger, L; Sellner, J;
EUR J NEUROL. 2019; 26: 822-822.
Abstracts (Zeitschrift)
Chronic inflammatory demyelinating polyneuropathy with anti-contactin-1 antibody: a case report
Poppert, KN; Kleindienst, W; Rosler, C; Neuray, C; Kunz, AB; Leitinger, M; Moser, T; Grinzinger, S; Hoftberger, R; Sellner, J;
EUR J NEUROL. 2019; 26: 900-900.
Abstracts (Zeitschrift)
2017
Beiträge in Fachzeitschriften
Autoimmune Encephalitis at the Neurological Intensive Care Unit: Etiologies, Reasons for Admission and Survival.
Harutyunyan, G; Hauer, L; Dünser, MW; Karamyan, A; Moser, T; Pikija, S; Leitinger, M; Novak, HF; Trinka, E; Sellner, J;
Neurocrit Care. 2017; 27(1):82-89
Originalarbeiten (Zeitschrift)
Risk Factors for Intensive Care Unit Admission in Patients with Autoimmune Encephalitis.
Harutyunyan, G; Hauer, L; Dünser, MW; Moser, T; Pikija, S; Leitinger, M; Novak, HF; Aichhorn, W; Trinka, E; Sellner, J;
Front Immunol. 2017; 8:835
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
The immune receptor expression pattern in peripheral-blood associated with JCV seropositivity in patients with multiple sclerosis is not affected by natalizumab
Harrer, A; Frommrich, M; Moser, T; Afazel, S; Haschke-Becher, E; Wipfler, P; Sellner, J
MULT SCLER J. 2017; 23: 337-338.
Abstracts (Zeitschrift)
Risk factors for intensive care unit admission in patients with autoimmune encephalitis
Harutyunyan, G; Pikija, S; Moser, T; Dunser, M; Leitinger, M; Novak, H; Aichhorn, W; Trinka, E; Hauer, L; Sellner, J
EUR J NEUROL. 2017; 24: 19-20.
Abstracts (Zeitschrift)
Natalizumab-related progressive multifocal leukoencephalopathy in Austria: An observational nationwide study
Moser, T; Fertl, E; Koppi, S; Seifert-Held, T; Safoschnik, G; Bsteh, G; Heller, T; Rommer, P; Baumgartner, A; Berger, T; Sellner, J
EUR J NEUROL. 2017; 24: 38-38.
Abstracts (Zeitschrift)